Bioinformatics Firms See Microsoft Acquisition of Rosetta Biosoftware as Boost for the Field

Some bioinformatics software firms are prepping for the possibility that Microsoft will come knocking at their doors, since the software giant will likely want to fill some additional gaps in its life science offering. Others, however, noted that they will now have to prepare for a new, deep-pocketed competitor in their market niche.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.